Vertex Pharmaceuticals Incorporated VRTX
NASDAQ
| 09/30/2026 | 06/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 3.21% | 11.62% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3.21% | 11.62% | |||
| Cost of Revenue | 6.26% | 9.49% | |||
| Gross Profit | 0.76% | 13.38% | |||
| SG&A Expenses | 10.12% | 17.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.35% | 11.75% | |||
| Operating Income | -3.53% | 11.41% | |||
| Income Before Tax | -43.71% | 11.09% | |||
| Income Tax Expenses | -55.55% | 31.83% | |||
| Earnings from Continuing Operations | -40.57% | 6.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -40.57% | 6.63% | |||
| EBIT | -3.53% | 11.41% | |||
| EBITDA | -2.42% | 10.92% | |||
| EPS Basic | -40.52% | 6.80% | |||
| Normalized Basic EPS | -9.06% | 13.97% | |||
| EPS Diluted | -40.60% | 7.21% | |||
| Normalized Diluted EPS | -9.13% | 14.28% | |||
| Average Basic Shares Outstanding | -0.08% | -0.16% | |||
| Average Diluted Shares Outstanding | 0.00% | -0.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||